Plasma Pyridostigmine Levels in Myasthenia Gravis
Neurol 31:145-150, White,M.C.,et al, 1981
Malabsorption of Pyridostigmine in Patients with Masthenia Gravis
Neurol 27:299, Cohan,S.L.,et al, 1977
A Child with Arthrogryposis
Neurol 91:e995-e998, Irumudomom, O. & Ghosh, P.S., 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
BMJ 345:e8497, Spillane, J.,et al, 2012
Treatment of Ocular Symptoms in Myasthenia Gravis
Neurol 71:1335-1341, Bhanushali,M.J.,et al, 2008
Ocular Myasthenia Gravis Treatment: The Case Against Prednisone Therapy and Thymectomy
Arch Neurol 64:1790-1792,1794, Gilbert,M.E.,et al, 2007
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Myasthenia Gravis in Mothers and Their Newborns
Clin Obstet Gynecol 34:82-99, Plauche,W.C., 1991
Citrate-Induced Impairment of Neuromuscular Transmission in Human and Experimental Autoimmune Myasthenia Gravis
Ann Neurol 27:328-330, Wirguin,I.,et al, 1990
Left-handedness:Association with Immune Disease, Migraine, & Developmental Learning Disorder
Proc Natl Acad Sci 79:5097-5100, Geschwind,N.,et al, 1982
Controversies About the Treatment of Myasthenia Gravis
JNNP 43:644-659, Rowland,L.P., 1980
Narcolepsy
NEJM 288:1156, Zarcone,V., 1973
Neurological Problems in Endocrine Diseases
Med Clin North Am 56:1029, Dale,A., 1972
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Curtain Sign
NEJM 387:e7, Sherman, S.V., 2022
Myasthenia Grais
www.mda.org, , 2021
A 68-Year-Old Man with Proximal Weakness and Seizures
Neurol 97:e423-e428, Chen, T., 2021
A 71-Year-Old Man Presenting with Acute Onset Dysarthria and Dysphagia
Neurol 96:180-184, Spagni, G.,et al, 2021
Useful Bedside Testing for Myasthenia Gravis
Neurol 94:e1870-e1871, Gomes del Carvalho Neto, E.,et al, 2020
Thymectomy for Myasthenia Gravis
Neurol 94:705-709, Gronseth, G.S.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
The Face of Myasthenia Gravis
Neurol 95:89-90, Ruiter, A.M.,et al, 2020
Ptosis that Resolves with Application of an Ice Pack
BMJ 369:m1147, Chakraborty, A. & Jacob, J., 2020
Acetylcholine Receptor-Antibody-Positive Myasthenia Gravis Presenting with Early Atrophy and Nonfluctuating Weakness of Proximal Limb Muscles
J Clin Neurol 16:714-716, Pancheri, E.,et al, 2020
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020
Long-Term Follow-Up, Quality of Life, and Survival of Patients with Lambert-Eaton Myasthenic Syndrome
Neurol 94:e511-e520, Lipka, A.F.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Drug Approved for Rare Muscle Weakening Syndrome
JAMA 321:239, Voelker, R., 2019
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Bilateral Cavernous Carotid Aneurysms: Atypical Presentation of a Rare Cause of Mass Effect
Front Neurol doi:10.3389/fneur.2018.0069, Gagliardi, D.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Dont Fall for Pseudo-INO
Neurol 88:e205-e206, Traber, G.L.et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017